Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980460 | 0.79 | BAZ1A (0.37) | MAPTMEN1KMT2AMCL1CASP1 | |
| SCHEMBL1025369 | 0.79 | ALDH1A1 (0.40) | MAPTCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL7894568 | 0.79 | ATM (0.42) | MAPTCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL1090688 | 0.79 | ALDH1A1 (0.51) | MAPTKMT2AMCL1CASP1CASP7 | |
| SCHEMBL6204798 | 0.79 | MAPK1 (0.42) | MAPTCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL27087781 | 0.78 | KDM4E (0.45) | MAPTMEN1KMT2APOLBMCL1 | |
| SCHEMBL460543 | 0.77 | CASP1 (0.57) | MEN1KMT2ACASP1CASP7HSD17B10 | |
| SCHEMBL2246168 | 0.77 | MAPT (0.49) | MAPTMEN1KMT2APOLBMCL1 | |
| SCHEMBL7162505 | 0.76 | TYMS (0.53) | MAPTKMT2AMCL1CASP1CASP7 | |
| SCHEMBL30957320 | 0.76 | PGR (0.42) | MAPTCASP1CASP7HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338487-B2 | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | ORAPHARMA, INC. | 2011-08-25 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960436-B2 | Therapy and prophylaxis of diseases and disorders such as seizure disorders; [1-Amino-5-(4-trifluoromethyl-phenylamino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-carbamic acid ethyl ester | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207812-A1 | SUBSTITUTED ARYLAMINO-1,2,3,4-TETRAHYDRO NAPHTHALENES AND -2,3-DIHYDRO-1H-INDENES AS POTASSIUM CHANNEL MODULATORS | SCN1B, SCN1A, SCN4A | MAPT 3337/4885MEN1 1428/4885KMT2A 1509/4885 |
| US-20080146661-A1 | Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators | SCN1B, SCN1A, SCN4A | MAPT 3170/4885MEN1 1344/4885KMT2A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.